A growth-hormone-releasing peptide studied for metabolic and body-composition support.
Tesamorelin is a trans-3-hexenoic acid-modified GHRH analog studied for its stable engagement of pituitary GHRH receptors. Research and clinical data suggest it supports endogenous GH pulse amplitude and downstream IGF-1 pathway activity, which is associated with lipid mobilization, lean mass preservation, and metabolic substrate regulation. Its structural modification supports extended receptor engagement compared to native GHRH. Intended for research purposes.


Tesamorelin is a stabilized GHRH analog studied for its engagement of pituitary GHRH receptors. Research and clinical data suggest it supports GH pulse amplitude and downstream IGF-1 activity, associated with lipid mobilization, lean mass preservation, and metabolic substrate regulation, with its structural modification supporting extended receptor engagement versus native GHRH.
Research Use Only. These products have not been evaluated or approved by the FDA for use as drugs, therapeutics, diagnostics, or dietary supplements, and are not intended for administration to humans or animals. No product description or mechanism-of-action information constitutes a health claim or therapeutic endorsement. Any clinical use is at the sole discretion of a licensed healthcare provider in compliance with applicable laws. Individual results may vary.